Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
about
hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.A key role for peroxynitrite-mediated inhibition of cardiac ERG (Kv11.1) K(+) channels in carbon monoxide-induced proarrhythmic early afterdepolarizations.Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.The Basis for Low-affinity hERG Potassium Channel Block by Sotalol.An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived CardiomyocytesMolecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details.Multiple clinical profiles of families with the short QT syndrome.Probing the molecular basis of hERG drug block with unnatural amino acids.Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future ChallengesAction potential clamp characterization of the S631A hERG mutation associated with short QT syndrome
P2860
Q36085808-86787351-50E6-478C-8C8F-6B5316C7D0DAQ38661585-01ACDC1F-0DD9-4DD8-8272-6AA385628FA3Q40376134-6D7EFF26-7E30-4033-A878-D775CD88E447Q42021474-D72D116A-823F-443E-A182-DF2F7769FAB9Q42173245-3808617E-D041-4AA7-B957-3DF9C1A18287Q42699631-AAADF6C5-AEFB-4999-9A3A-7F114124E0CFQ42700209-035B8DC7-20AE-4352-9CF7-AE85A9091190Q43070404-8DCEC5FE-0D82-481B-9828-294C6BF54B24Q47095257-422F35FE-8632-42B1-AC5B-C1EEE0684DD9Q47827561-B4C7FA15-B88E-4234-BB89-2A2571AE2C47Q48267422-D80F8D79-2584-43DB-91A5-CDBCBA867A04Q53837170-AC3B0783-9CE0-4523-96C0-446AEBC776CCQ57161239-1D365D2E-56E2-409B-9EE3-BC9088EF8EFAQ58770371-60FD03A9-B349-4656-8E84-A1D1D983C0C1
P2860
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Ranolazine inhibition of hERG ...... against inactivation mutants.
@en
Ranolazine inhibition of hERG ...... against inactivation mutants.
@nl
type
label
Ranolazine inhibition of hERG ...... against inactivation mutants.
@en
Ranolazine inhibition of hERG ...... against inactivation mutants.
@nl
prefLabel
Ranolazine inhibition of hERG ...... against inactivation mutants.
@en
Ranolazine inhibition of hERG ...... against inactivation mutants.
@nl
P2093
P2860
P1476
Ranolazine inhibition of hERG ...... against inactivation mutants.
@en
P2093
Chunyun Du
Jules C Hancox
Yihong Zhang
P2860
P304
P356
10.1016/J.YJMCC.2014.05.013
P577
2014-05-27T00:00:00Z